CBIO
NASDAQCrescent Biopharma Inc.
Price$14.78+0.30 (+2.11%)
01:30 PM07:45 PM
News · 26 weeks60+90%
2026-01-182026-07-12
Mix4290d
- SEC Filings15(36%)
- Insider12(29%)
- Other11(26%)
- Offering3(7%)
- Analyst1(2%)
Latest news
25 items- PRCrescent Biopharma Announces Closing of Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional SharesWALTHAM, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has closed its previously announced underwritten public offering of 9,387,896 ordinary shares, including 1,293,103 ordinary shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares were sold to the public at a price of $14.50 per share and the pre-funded
- SECCrescent Biopharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECSEC Form 424B5 filed by Crescent Biopharma Inc.424B5 - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- PRCrescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded WarrantsWALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced the pricing of its underwritten public offering of 8,094,793 ordinary shares and in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 525,897 ordinary shares. The ordinary shares are being sold to the public at a price of $14.50 per share and the pre-funded warrants are being sold at a price to the public of $14.499 per pre-funded warrant, which represents the per ordinary share price less the $0.001 per sh
- SECCrescent Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECSEC Form 424B5 filed by Crescent Biopharma Inc.424B5 - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- PRCrescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded WarrantsWALTHAM, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that it has commenced an underwritten public offering of its ordinary shares or, in lieu of ordinary shares to investors that so choose, pre-funded warrants to purchase its ordinary shares. In addition, Crescent intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares at the public offering price, less underwriting discounts and commissions. All of the ordinary shares and pre-funded warran
- SECSEC Form EFFECT filed by Crescent Biopharma Inc.EFFECT - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECSEC Form S-3 filed by Crescent Biopharma Inc.S-3 - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- PRCrescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 65,100 shares of the Company’s ordinary shares to three non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on June 25, 2026 and were material to each employee's acceptan
- INSIDEROfficer Lynch Ryan sold $8,365 worth of Ordinary Shares (465 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 13,871 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERChief Scientific Officer Pinkas Jan sold $23,171 worth of Ordinary Shares (1,288 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 22,239 units (SEC Form 4) to satisfy withholding obligation4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDEROfficer Bispham Barbara Harlin sold $21,912 worth of Ordinary Shares (1,218 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 19,330 units (SEC Form 4) (for withholding tax)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERChief Financial Officer Scalzo Richard William sold $20,005 worth of Ordinary Shares (1,112 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 20,298 units (SEC Form 4) (tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERChief Medical Officer Im Ellie Eunkyung sold $21,930 worth of Ordinary Shares (1,219 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 22,069 units (SEC Form 4) (withholding obligation)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERPresident and COO Mcneill Jonathan sold $369,677 worth of Ordinary Shares (20,549 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 139,158 units (SEC Form 4) (for tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERChief Executive Officer Brumm Joshua T sold $761,067 worth of Ordinary Shares (42,305 units at $17.99) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 281,212 units (SEC Form 4) (tax liability)4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- SECSEC Form 424B3 filed by Crescent Biopharma Inc.424B3 - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- SECAmendment: SEC Form 10-Q/A filed by Crescent Biopharma Inc.10-Q/A - CRESCENT BIOPHARMA, INC. (0001253689) (Filer)
- PRCrescent Biopharma Announces Grants of Inducement AwardsWALTHAM, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. ("Crescent" or the "Company") (NASDAQ:CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 23,550 shares of the Company's ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the "Inducement Plan"). The options were approved on June 10, 2026 and were material to each employee's acceptance
- INSIDERSEC Form 4 filed by Director Violin Jonathan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERSEC Form 4 filed by Director Lubner David Charles4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERSEC Form 4 filed by Director Balcom Alexandra4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERSEC Form 4 filed by Director Moran Susan4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - CRESCENT BIOPHARMA, INC. (0001253689) (Issuer)
CBIO FAQ
7 questionsWhat does Crescent Biopharma Inc. do?
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company engineer proteases to develop improved or novel molecules to treat diseases that result from dysregulation of the complement and coagulation cascades. Its protease engineering platform has generated two late-stage clinical programs, including marzeptacog alfa (MarzAA), a subcutaneously administered engineered coagulation; and Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare...Where does CBIO stock trade?
Crescent Biopharma Inc. (CBIO) is listed on NASDAQ.What sector and industry is CBIO in?
Crescent Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Crescent Biopharma Inc. go public?
Crescent Biopharma Inc. (CBIO) completed its IPO in 2014.What are analysts saying about CBIO?
Crescent Biopharma Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-06-01. Recent price targets range from $2500.00 to $3500.00.What companies are similar to CBIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CBIO side-by-side with any of them on Quantisnow.How can I track CBIO on Quantisnow?
Quantisnow aggregates Crescent Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CBIO to receive live email and push alerts on every new disclosure.